p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy

BACKGROUND: We attempted to elucidate whether p53 expression or TP53 mutation status was associated with cancer-specific survival in adjuvant FOLFOX-treated patients with stage III or high-risk stage II colorectal cancer (CRC). METHODS: We analysed CRCs (N = 621) for the presence of TP53 alterations...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Oh, Hyeon Jeong, Bae, Jeong Mo, Wen, Xianyu, Jung, Seorin, Kim, Younghoon, Kim, Kyung Ju, Cho, Nam-Yun, Kim, Jung Ho, Han, Sae-Won, Kim, Tae-You, Kang, Gyeong Hoon
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6474280/
https://ncbi.nlm.nih.gov/pubmed/30894685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0429-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars